secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2021-10-26T23:59:59+00:00
Accession:  0000059478-21-000213
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab
--------------------------------------------------------------------------------

- Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).
- Key growth products (Trulicity +45%, Verzenio +43%) drove 17pp of growth; COVID-19 antibody revenue $423.5M.
- Submitted tirzepatide NDA for type 2 diabetes with priority review voucher; initiated rolling submission for donanemab in early Alzheimer's.
- FDA approved Verzenio for high-risk early breast cancer and Jardiance for HFrEF; positive Phase 3 for lebrikizumab in atopic dermatitis.
- Repurchased higher-cost debt ($405.2M charge); issued €600M sustainability bond.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/0000059478-21-000213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/lly-20211026.htm
  HTML page:      https://secwatch.observer/filing/0000059478-21-000213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer